Patents by Inventor Kyung Ah Jung

Kyung Ah Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251155
    Abstract: The present invention relates to: a recombinant peptide in which a Mitochondria Localization Sequence (MLS) peptide and the Signal Transducer and Activator of Transcription 3 (STAT3) are fused to each other; a recombinant vector carrying a polynucleotide coding for the recombinant peptide; and a composition comprising the recombinant peptide or the recombinant vector as an active ingredient for prevention or treatment of autoimmune disease or inflammatory disease, wherein the recombinant peptide or the recombinant vector allows STAT3 to be overexpressed in the mitochondria to enhance the mitochondrial function, resulting in inhibiting the expression of inflammatory cytokines including IL-17, whereby the composition may be advantageously used for preventing or treating autoimmune disease or inflammatory diseases.
    Type: Application
    Filed: January 28, 2020
    Publication date: August 11, 2022
    Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Mi-La CHO, Sung-Hwan PARK, Seon-Yeong LEE, Su-Jin MOON, Eun-kyung KIM, Jun-Geol RYU, Si-Yeong CHOI, Jeong-Won CHOI, Kyung-Ah JUNG, A-Ram LEE, Chul-Woo YANG, Jeong-Hyeon MOON
  • Patent number: 9752151
    Abstract: The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: September 5, 2017
    Assignees: The Asan Foundation, University of Ulsan Foundation for Industry Cooperation
    Inventors: Tae Won Kim, Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin, Jin Sun Kim, Kyung Ah Jung, Jung Shin Lee, Eun Kyung Choi, Jae Lyun Lee, Yong Sang Hong, Kyu Pyo Kim, Ky Youb Nam, Bong Cheol Kim
  • Publication number: 20160040168
    Abstract: The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.
    Type: Application
    Filed: March 27, 2014
    Publication date: February 11, 2016
    Inventors: Tae Won Kim, Dong Hoon Jin, Seung Woo Hong, Jai Hee MOON, Jae Sik Shin, Jin Sun Kim, Kyung Ah Jung, Jung Shin Lee, Eun Kyung Choi, Jae Lyun Lee, Yong Sang Hong, Kyu Pyo Kim, Ky Youb Nam, Bong Cheol Kim